Trial 2N-20-6


An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments: Biological Response Modifier
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Jorge Nieva, M.D.
Other Trial Staff:  Grace Facio, Coordinator, Marissa Aldana, D.M., Mary Ordaz, D.M., Margarita Carranza, D.M., Eduardo Mejia, D.M., America Casillas-Lopez, Coordinator, Niranjan Bhatt, D.M., Apoorva Vishwanath, D.M., Ramy Farag, Coordinator, Brigitte Torres, Coordinator, Sreebharathy Venkatesh, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.